Elidel: Advanced Non-Steroidal Eczema and Dermatitis Relief
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 1 | $50.20 | $50.20 (0%) | 🛒 Add to cart |
| 2 | $45.18 | $100.40 $90.36 (10%) | 🛒 Add to cart |
| 3 | $40.16 | $150.60 $120.48 (20%) | 🛒 Add to cart |
| 4 | $37.65 | $200.80 $150.60 (25%) | 🛒 Add to cart |
| 5 | $34.14 | $251.00 $170.68 (32%) | 🛒 Add to cart |
| 6 | $30.12 | $301.20 $180.72 (40%) | 🛒 Add to cart |
| 7 | $27.25 | $351.41 $190.76 (46%) | 🛒 Add to cart |
| 8 | $25.10 | $401.61 $200.80 (50%) | 🛒 Add to cart |
| 9 | $23.43 | $451.81 $210.84 (53%) | 🛒 Add to cart |
| 10 | $22.09
Best per tube | $502.01 $220.88 (56%) | 🛒 Add to cart |
Synonyms | |||
Elidel (pimecrolimus) Cream 1% is a topical immunomodulator specifically formulated for the short-term and intermittent long-term treatment of mild to moderate atopic dermatitis (eczema) in non-immunocompromised patients aged 2 years and older, for whom conventional therapies are inadvisable, have failed, or cannot be tolerated. It functions by selectively inhibiting T-cell activation and the release of inflammatory cytokines, providing targeted control without the risks associated with prolonged corticosteroid use. Clinical studies demonstrate its efficacy in reducing pruritus, erythema, and lichenification, making it a cornerstone in modern dermatological management for appropriate patient populations.
Features
- Contains pimecrolimus 10 mg/g (1%) as the active pharmaceutical ingredient
- White, homogeneous cream formulation for optimal skin absorption
- Available in 15g, 30g, and 60g tubes with precise dosing guidance
- Non-greasy, fragrance-free base suitable for sensitive skin
- pH-balanced formulation to minimize irritation potential
- Manufactured under strict pharmaceutical quality control standards
Benefits
- Provides rapid relief from itching and inflammation within days of initiation
- Reduces eczema flares and extends remission periods with proper maintenance therapy
- Avoids skin atrophy, striae, and other corticosteroid-associated adverse effects
- Suitable for application on face, neck, and other sensitive skin areas
- Enables proactive management at first signs of symptom recurrence
- Supports restoration of skin barrier function with continued appropriate use
Common use
Elidel Cream is primarily indicated for the treatment of mild to moderate atopic dermatitis in patients 2 years of age and older. It is particularly valuable for managing sensitive areas such as the face, eyelids, and skin folds where corticosteroids might be problematic. Dermatologists frequently prescribe it as second-line therapy or for patients experiencing adverse effects from topical corticosteroids. The medication is suitable for intermittent use over extended periods, though continuous application beyond 6 weeks without reevaluation is not recommended.
Dosage and direction
Apply a thin layer of Elidel Cream twice daily to affected areas. Gently rub into the skin until absorbed. Use only on affected areas and avoid occlusive dressings unless directed by a healthcare provider. Treatment should begin at first signs of eczema symptoms and continue until complete clearance. If signs and symptoms persist beyond 6 weeks, reevaluate the diagnosis and treatment approach. For maintenance therapy, apply at earliest signs of recurrence to prevent full flare development. Wash hands after application unless hands are treated areas.
Precautions
Avoid exposure to natural or artificial sunlight (tanning beds, UVA/UVB treatment) during treatment periods. Wear protective clothing and use broad-spectrum sunscreen if sun exposure cannot be avoided. Do not use on areas with active viral infections (herpes simplex, varicella). Monitor patients for lymph node enlargement during extended use. Not recommended for use in immunocompromised patients. Avoid application to areas with premalignant or malignant skin conditions. Use the smallest amount needed to control symptoms. Do not apply to infected areas unless infection is being appropriately treated.
Contraindications
Hypersensitivity to pimecrolimus or any component of the formulation. Patients with Netherton’s syndrome or other skin barrier defects. Use in children under 2 years of age. Application to active cutaneous infections (bacterial, viral, fungal). Patients with known genetic immunodeficiencies or undergoing immunosuppressive therapy. Individuals with history of lymphoproliferative disorders. Not for ophthalmic use, including application on eyelids if risk of eye exposure exists.
Possible side effects
Most common side effects include application site burning (26%), headache (6.5%), and nasopharyngitis (6.2%). Other reported reactions include cough, fever, viral skin infections, and acne. Rare cases of skin malignancy and lymphoma have been reported, though causal relationship remains uncertain. Some patients experience flushing or warmth at application site, particularly with alcohol consumption. Localized reactions typically diminish within first few days of treatment. Systemic absorption is minimal with appropriate use.
Drug interaction
No formal drug interaction studies have been conducted. Theoretical interactions exist with other immunosuppressants, though systemic absorption is minimal. Caution with concomitant use of CYP3A4 inhibitors (ketoconazole, erythromycin) though clinical significance is likely low due to limited systemic exposure. No known interactions with vaccines, though avoid application on recently vaccinated skin. Separate application from other topical medications by at least 30 minutes.
Missed dose
Apply as soon as remembered unless almost time for next scheduled dose. Do not double application to make up for missed dose. Resume regular dosing schedule. If multiple doses are missed and symptoms worsen, contact healthcare provider for guidance on reinitiating therapy.
Overdose
Topical overdose is unlikely due to minimal systemic absorption. Excessive application might increase risk of local adverse effects. If accidental ingestion occurs, seek medical attention immediately. Gastrointestinal symptoms might occur. No specific antidote exists; provide supportive care based on symptoms. Dialysis is not expected to be effective due to high protein binding and extensive metabolism.
Storage
Store at room temperature (15-30°C). Do not freeze. Keep tube tightly closed when not in use. Protect from excessive heat and direct sunlight. Keep out of reach of children. Do not use beyond expiration date printed on packaging. Discard any cream that has changed color or consistency.
Disclaimer
This information does not replace professional medical advice. Consult qualified healthcare provider for diagnosis and appropriate treatment decisions. Use only as directed by prescribing physician. Report any adverse reactions to healthcare provider and appropriate regulatory authorities. Individual results may vary based on patient factors and disease severity.
Reviews
Clinical trials demonstrate 51-61% of patients achieving clear or almost clear skin after 6 weeks of treatment. Pediatric studies show significant improvement in quality of life scores and sleep parameters. Long-term safety studies (up to 2 years) support intermittent use with maintained efficacy. Dermatologists report high patient satisfaction particularly for facial and sensitive area application. Real-world evidence confirms reduction in corticosteroid use and flare frequency with proper maintenance therapy.